Iain A. McIntyreMark D. Schuman | Todd S. Werner

Our client filed an ANDA including a Paragraph IV challenge of Elan’s patents covering the formulation of Celgene’s Focalin® (dexmethylphenidate) extended release tablets. Carlson Caspers represented Teva in the ensuing Hatch-Waxman patent litigation, and negotiated a settlement favorable to our client.